29 Mar

Get the Inside Scoop on Seattle Life Sciences at Xconomy’s June Event

Xconomy’s annual Seattle-area life sciences conference will be held on June 12 at Cambia Grove in the Emerald City’s downtown. “What’s Hot in Seattle Biotech” will look at what’s hot, and what’s next, for the Puget Sound region’s life sciences scene. It’s only March , but already this year, Seattle’s life science community has seen two major deals-Microsoft and Adaptive Biotechnologies kicked off 2018 announcing a partnership aiming to apply artificial intelligence and machine learning to map the immune system, and cancer drug developer Juno Therapeutics reached a deal to be acquired by Celgene for approximately $9 billion. What else can… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

29 Mar

Research Headlines – Faster future vaccine design

[Source: Research & Innovation] Glycoconjugate vaccines provide highly effective protection against disease. But so far, they have been developed by time-consuming trial and error. Now, an EU-funded project is building up knowledge and skills to better design these vaccines in a bid to bring treatments to patients faster and keep European pharmaceutical innovation competitive.

29 Mar

BIO2018: Robin Roberts, Diana Ross and Record-breaking Partnering

As BIO celebrates its 25-year anniversary, the upcoming BIO International Convention June 4-7 at the Boston Convention and Exhibition Center will highlight the organization’s past and imagine the future. With the theme and tagline, “make history”, BIO 2018 will be remembered for its high-profile speakers, over 16,000 attendees, 1,800 exhibitors, record breaking partnering meetings, stellar education program, global pavilions and super fun networking events.

The first keynote speaker was announced today: TV’s Robin Roberts. A well-known broadcast journalist, Roberts has conducted interviews with countless newsmakers, musicians, authors, athletes and celebrities. She was diagnosed with breast cancer in June 2007. Five years later after beating cancer, she was diagnosed with myelodysplastic syndrome (MDS), a rare disease of the blood and bone marrow once known as pre-leukemia. Roberts underwent a bone marrow transplant in September 2012 and has become an outspoken advocate for bone marrow donations and blood cancer research. The keynote session, will be held Tuesday, June 5 from 9-10:30 AM (EST).

Why Boston?

As the world’s epicenter of biotechnology innovation, Boston – which last hosted BIO in 2012 – is the prime location for BIO 2018. The city is home to nearly 1,000 biotech companies, academic centers, hospitals and life science centers advancing breakthrough research and product development. Over the last decade, Massachusetts has become a powerhouse for industry growth, with a 30 percent increase in jobs and no signs of slowing down. At last year’s convention, Governor Charlie Baker unveiled a 5-year, $500 million plan to increase infrastructure, research and development, and workforce training to continue building upon Massachusetts’ scientific excellence.

What to Expect

Registration is open for this year’s event, which promises to be the most comprehensive biotech convention in the world. BIO 2018 will offer:

  • Nineteen educational tracks, covering all sectors of biotechnology including genome editing, opioids, digital health, oncology, personalized medicine, food and agriculture and more.
  • Discussions by top thought leaders from:

    • Bill and Melinda Gates Foundation – Dr. Penny Heaton and Dr. Susan Desmond-Hellmann
    • Food and Drug Administration – Dr. Scott Gottlieb
    • Novartis – Dr. Jay Bradner
    • Merck – Kevin Ali, Dr. Christine Brennan, Dr. Julie Gerberding and Michael Nally
    • Sanofi – Dr. Heather Bell, Dr. Justin Huddleson, Dr. Adam Keeney and Stephen Meunier
    • Kraft Group and New England Patriots President – Jonathan Kraft

  • Engaging exhibits such as the Patient Advocacy Pavilion, Emerging Innovators Zone, Digital Health Zone, and Start-Up Stadium – a “Shark Tank”-like program where startups present to leading subject-matter experts in the industry.

Networking

BIO 2018 will play host to countless networking and partnering opportunities including receptions on Monday and Wednesday and Hospitality receptions on the exhibit floor at the end of the day on Tuesday.

Party-goers for Wednesday’s evening reception will be entertained by no other than DIANA ROSS!

Receptions are great for networking but BIO’s proprietary One-on-One Partnering™ program holds the key to making the right connections and building relationships-and it opens next week. The system allows attendees to identify potential partners and schedule meetings prior to the conference. In 2017, there were over 41,400 individual meetings held over the course of four days. Anyone registered for Convention Access + Partnering can use the system and the chances for getting the meetings you want improve the earlier you log in and set up your company profile.

Scheduling

With proper planning, in just four critical days, you can set up a full year of business connections, partnering possibilities and exposure to many innovations for the future of biotech. BIO offers a variety of programming, connection points and networking resources to ensure success. Begin by outlining your organization’s objectives (and a few personal ones too) and start evaluating how you can make the most of your time at BIO.

All of this points to Boston as the place to be from June 4-7 for you to “make history” with promising partnerships.  To learn more about the event and available registration packages, please visit convention.bio.org/register.

28 Mar

Edge to Cut Jobs as Head Injury Drug Flops in Phase 3, Shares Tumble

For years, Edge Therapeutics has been building towards a crucial test of a drug meant to combat the potentially delayed effects of aneurysms and severe head injuries. The plan fell apart this morning: the company will shutter the study and cut its workforce because its experimental treatment, EG-1962, is likely to fail.

An independent committee has performed an interim analysis of the first 210 patients in a study called NEWTON 2. The trial was set up to test whether Edge’s (NASDAQ: EDGE) drug, an injectable, sustained-release form of the pill nimodipine, was better than nimodipine pills at treating a… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

28 Mar

Research Headlines – Cultural heritage goes digital – and 3D

[Source: Research & Innovation] An EU-funded training network used advanced imaging techniques to scan and reconstruct ancient artefacts and monuments in digital form. This opens many opportunities for conservationists, researchers and museums – in both preserving Europe’s cultural heritage and educating people.

28 Mar

Mommy, Ph.D.: Prescribing Lessons in Biotechnology, One Troll At a Time

Like many mothers, Allison Bernstein was overwhelmed with the information about what makes food safe. So overwhelmed, in fact, she thought “everything was killing us, and everything was destroying her.”

However, that all changed when she started working at a toxicology lab, where the science around biotechnology cannot be misconstrued by the internet or the organic industry.

In a recent piece for the Lansing State Journal, reporter RJ Wolcott profiles Bernstein’s journey from science skeptic, influenced by misinformation perpetuated by the organic industry, to science advocate, engaging in healthy debate and providing education on biotechnology and GMOs through her blog Mommy, Ph.D.

Even in the wake of threats against her and her family, Bernstein continues to be a vocal critic of unscientific practices.

Alison Bernstein used to be a “fear-based mom.”

In the documentary “Science Moms,” she described feeling overwhelmed with dread that the food she brought from the store could have life-long impacts on her daughter.

Then, Bernstein got a job in a toxicology lab at Emory University in Atlanta.

“I thought I was going to go there and find out that everything was killing us and everything was destroying her.”

Instead, the experience helped her put exposure to various chemicals into the larger context of everyday life. For instance, she said, the same chemical that prompted outrage over its use as an artificial coloring in pumpkin spice lattes – 4-MEI – is naturally present in coffee, soy sauce, beer and bread.

Bernstein, who now works as an assistant professor of translational science and molecular medicine at Michigan State University’s College of Human Medicine in Grand Rapids, didn’t find that level of nuance and understanding online.

She found bloggers relying on their experience as mothers to make unscientific claims about the dangers of genetically engineered crops and vaccines.

“Pseudoscience and anti-science stuff provides really simple, easy answers,” Bernstein said. “It gives a clear boogeyman, like GMOs or vaccines, and a clear solution, and that is much easier to deal with.”

She decided to reserve a tongue-in-cheek name on Facebook for her own blog – Mommy, PhD. – in 2011, though she didn’t start writing it in earnest until a few years later.

“I welcome discussion,” Bernstein wrote under her rules section. “In fact, I love a good discussion about science. But I do not tolerate trolls.”

Challenging unscientific views online comes at a cost.

When Bernstein started blogging about GMOs and vaccines, she got messages wishing cancer upon her and her children. She asked her family to restrict their social media visibility out of fear that they would get harassed, too.

It hasn’t stopped her from being a vocal critic of unscientific practices. She sees real value in being both a mother with relatable interests who also can speak with authority on these topics.

“I think most people don’t have time to spend time reading the scientific literature, but it helps to know someone who is like them, someone they can trust, someone who is an expert also, has formed an opinion about something and can back it up if asked.”

Bernstein was asked by her Pilates instructor last fall about a poster hung inside the studio that highlighted produce with purportedly high levels of pesticides. Her instructor asked whether she trusted it. Bernstein said no, and after a two-minute conversation about why not, the instructor took the poster down.

“She didn’t want piles of data,” Bernstein said. “She just wanted to know that someone she knows and trusts, who is a scientist and has some knowledge of this, doesn’t trust it.”

Bernstein joined her fellow Science Moms last week for the first Michigan screening of the film at MSU.

Wearing a blue Science Moms necklace, she sat in front of a classroom of two dozen people and talked about her experiences bringing scientific understanding into online debates.

“She brings that science background and expertise but also communicates it so well,” said Natalie Newell, the filmmaker behind “Science Moms”. “I’m not an expert in science at all, but I can listen to her and understand what she’s saying and she’s a person I wanted in front of parents who might have fears.”

Bernstein also gets her daughters involved with her work. She uses her oldest’s Legos for comics, most recently introducing the villain Sue Doe Syence.

Her daughter even drew her a picture of a troll that she could use whenever someone attempted to subvert the comment section of the blog.

“Don’t feed the trolls” is one of Bernstein’s favorite adages.

One incident from 2015 was particularly upsetting for Bernstein and fellow science mom Kavin Senapathy, an author and co-executive director of March Against Myths, an organization that fights against misinformation.

Both of them are “Buffy the Vampire Slayer” fans. Sarah Michelle Gellar, who played Buffy on the television show, was among several celebrities who came out in favor of labeling GMOs out of concern for their potential impact on consumers.

Bernstein and Senapathy were among several scientists, farmers and science writers who put out an open letter in response. It read, in part, “Please, don’t co-opt motherhood and wield your fame to oppose beneficial technologies like genetic engineering.”

The National Academies of Sciences, Engineering and Medicine released a far-reaching report the following year that reaffirmed, in part, “no substantiated evidence that foods from (genetically engineered) crops were less safe than foods from non-GE crops.”

Still, the labeling GMOs movement persists, and labels saying that no GMOs were used in a given product can be found on products ranging from Cheerios to Ben and Jerry’s ice cream.

Worse than the anti-GMO advocates are the anti-vaccine proponents, Bernstein said. It was the measles outbreak in California in 2015 that pushed her to be more vocal as a mother and scientist.

She remembers being a graduate student at Washington University when Jenny McCarthy first started propagating the idea that vaccines were dangerous and linked to autism in the mid-to-late 2000s. The research underpinning McCarthy’s view has long since been discredited, but anti-vax beliefs continue to persist online.

Had scientists come out strongly against those claims earlier, maybe it wouldn’t have gotten so popular, Bernstein said.

Kristina Kamensky, a PhD candidate in mechanical engineering at MSU who came to the film screening, knows that challenge first-hand. Her father frequently uses cayenne pepper mixes rather than prescribed blood thinners. He doesn’t trust conventional medicine, which is concerning to Kamensky. Seeing Bernstein and her fellow Science Moms tackle misinformation is heartening, she said.

“It’s encouraging that success can happen after brief conversations with people.”

 

28 Mar

For Now, Traders Endorse Biotech Rally

Among leveraged and inverse biotechnology exchange-traded funds, the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) and the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD) are the dominant names. The fund flow data for these products can potentially prove instructive …

28 Mar

Roche reports 5 deaths after dosing of Hemlibra

Besides these, huge prices have been paid by Sanofi for licensing novel treatment approaches european-biotechnology.com/up-to-date/latest-news/news/sanofi-takes-over-bioverativ-in-us118bn-deal.html in the competitive market currently dominated by Shire (FEIBA) and Novo Nordisk (NovoSeven) …

27 Mar

Call for proposals to support awareness raising and information campaigns on the risks of irregular migration in selected third-countries

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: AMIF-2017-AG-INFOPillar: Legal migration and integrationOpening Date: Deadline: Thu, 5 Apr 2018 17:00:00 (Brussels local time)Modification Date: Tue, 27 Mar 2018Latest information: An updated Questions and Answers document has been published under the Topic of the Call.

27 Mar

EY Report Suggests Improving Conditions for U.S. IPOs in 2018

Nasdaq Tower Nasdaq (Used with Permission Copyright 2014 NASDAQ OMX Group)

U.S. IPO activity has been ticking up, with 36 IPOs raising more than $12.7 billion in the United States so far this year, according to data released Monday by EY, the global consulting and accounting firm.

Although there are still several days remaining in the first quarter of 2018, EY reports the number of first-quarter IPOs is 44 percent higher than the 25 offerings that occurred in the first quarter of 2017. The $12.7 billion total raised was almost 17 percent higher than the $10.9 billion raised in IPOs nationwide in the same quarter last year.

The increase is encouraging because… Read more »

UNDERWRITERS AND PARTNERS